The “Children’s Vision Equity Alliance” was created to advance equity in children’s vision and eye health.

“Through the new CVEA, we are working collaboratively with leaders, stakeholders and advocates to make sure we evolve and grow to effectively and strategically respond to the needs of families in underserved populations and communities,” said Jeff Todd, president and CEO of Prevent Blindness.

CHICAGO (PRWEB)
November 17, 2021

For more than 10 years, The National Center for Children’s Vision and Eye Health at Prevent Blindness (NCCVEH) has worked to ensure that children across the country have equitable access to quality vision and eye care services. To further this commitment, the NCCVEH is working with other leading stakeholders to establish The Children’s Vision Equity Alliance (CVEA). By bringing together experts and resources from eye health, education and public health organizations in the United States, the CVEA will work to advance equity in children’s vision and eye health through education, access, policies, and partnerships.

According to the recent report from the NCCVEH, “Children’s Vision and Eye Health: A Snapshot of Current National Issues 2nd Edition,” children experiencing health and socioeconomic inequities have lower rates of vision testing, experience disparities in visual impairment, and have reduced access to care. Additionally, Latino and Black/African-American children are two to three times more likely to have unmet vision needs. Without early detection and treatment, uncorrected vision disorders can impair child development, interfere with learning, and even lead to permanent vision loss.

To help address these challenges, the initial goals of the CVEA are to:

• 
  Foster education about the role of vision in the learning, health, and development of children in the target population of underserved communities of color (specifically Black/African-American, Indigenous and Latinx communities), beginning with a social media campaign to educate targeted populations.
• Advocate for policies and practices to support equitable access to vision care for children.
• Develop partnerships to support healthy vision and eye health equity for children.
• Continue to attract leaders from the fields of ophthalmology, optometry, public health, school nursing, early childhood care and education, medical care, and parent education and engagement who work toward health equity.

“Since our founding in 1908, Prevent Blindness has worked to ensure all children have the eye care access they deserve to enjoy healthy vision across their lifetimes,” said Jeff Todd, president and CEO of Prevent Blindness. “Through the new Children’s Vision Equity Alliance, coordinated by our National Center for Children’s Vision and Eye Health at Prevent Blindness, we are working collaboratively with leaders, stakeholders and advocates to make sure we evolve and grow to effectively and strategically respond to the needs of families in underserved populations and communities.”

In 2009, Prevent Blindness, with support from the Maternal and Child Health Bureau at the Health Resources and Services Administration of the U.S. Department of Health and Human Services, established the NCCVEH. The mission of the NCCVEH is to develop a coordinated public health infrastructure to promote and ensure a comprehensive, multi-tiered continuum of vision care for children. In 2019 and 2020, the NCCVEH provided technical assistance to more than 35 states, several national organizations, and Community of Practice teams across the country. In total, assistance was provided to 4,895 professionals, impacting 2,927,000 children across the nation.

For more information about The Children’s Vision Equity Alliance or children’s vision health topics, please visit https://nationalcenter.preventblindness.org/childrens-vision-equity-alliance or contact Donna Fishman at (800) 331-2020 or dfishman@preventblindness.org.

About Prevent Blindness and its National Center for Children’s Vision and Eye Health

Founded in 1908, Prevent Blindness is the nation’s leading volunteer eye health and safety organization dedicated to fighting blindness and saving sight. Focused on promoting a continuum of vision care, Prevent Blindness touches the lives of millions of people each year through public and professional education, advocacy, certified vision screening and training, community and patient service programs and research. In 2009, Prevent Blindness established the National Center for Children’s Vision and Eye Health (NCCVEH), with support from the federal Health Resources and Services Administration’s Maternal and Child Health Bureau. Serving as a national resource for the establishment of a public health infrastructure, the NCCVEH advances and promotes children’s vision and eye care, providing leadership and training to public entities throughout the United States. The NCCVEH is advised by a committee of national experts and leaders from the fields of ophthalmology, optometry, pediatrics, nursing, family advocates and public health to guide the work and recommendations of the NCCVEH. For more information, or to make a contribution to the sight-saving fund, call 1-800-331-2020. Or, visit us on the Web at http://nationalcenter.preventblindness.org.

Share article on social media or email:

“I couldn’t be more proud of this team and the many ways we’ve evolved and improved, especially in the last year,” shares Haley Devlin, COO for Stratasan. “The Stratasan team is special, and our openness to change is one of the many things that make us so strong.”

NASHVILLE, Tenn. (PRWEB)
November 17, 2021

Stratasan, an industry leader in healthcare data software, analytics, and services, is closing out 2021 with record growth and continued success. In its 10th year, Stratasan expanded its workforce by 33% (with seven additional positions currently open) and has effectively transitioned to a fully-remote workforce, with 30% of the team distributed across the country. The implementation of an ongoing Diversity, Equity, and Inclusion (DEI) initiative has benefited the entire Stratasan team and overall corporate culture. Stratasan is ending the year on a high note, having recently been recognized by The Nashville Entrepreneur Center as the 2021 Technology Market Mover and by making the 2021 Inc. 5000 list for a second time.

Stratasan’s commitment to being core-value focused, and its diligence to invite employee input into company culture discussions, are key reasons for the team’s lasting rapport. Having fully committed to distributed work at the end of 2020—as outlined in this Slideshare deck—the leadership team has encouraged open communication to address issues that could arise during the transition. In response to employee feedback, two wellness initiatives were launched, ‘Second Fridays’, which grants everyone in the company the second Friday of every month off to rest and recharge, and weekly “virtual watercooler chats” via a Slack integration with Donut. A recent employee survey highlighted that over 85% of the workforce feels engaged and supported by the senior leadership team, a statistic that reinforces why nearly one-third of Stratasan’s employees have been with the company for more than five years.

“I couldn’t be more proud of this team and the many ways we’ve evolved and improved, especially in the last year,” shares Haley Devlin, COO for Stratasan. “The Stratasan team is special, and our openness to change is one of the many things that make us so strong.”

In 2021, Stratasan partnered with a third party, Courage Collective, to launch an organization-wide DEI initiative. The goals of this partnership are to better understand DEI overall and to receive training that can make a lasting personal and professional impact on team members. Stratasan’s leadership was motivated to form this partnership and create space for empathetic, safe, and intentional conversations, to lead the way for continuous improvement in the future.

“Stratasan is dedicated to providing a positive and inclusive work environment for every member of its team,” shared Dani Marrero, HR Director for Stratasan. “Our experience with Courage Collective has proven to be an extremely beneficial team-building endeavor.”

The Stratasan team is ending the year celebrating its growth and feeling grateful for the industry recognition it received. As May marked 10 years since the company’s inception, the team has reflected on its early ties to the Nashville Entrepreneur Center (EC), as they were EC’s first participants, and how this relationship has continued to flourish over the years. Notable awards received this year include the NEXT Award for Technology Market Mover, The Startup Weekly’s Exceptional Workplace Award, Jason Moore, Stratasan’s Founder and CEO being recognized as Entrepreneur of the Year by the Nashville Business Journal, and recognition on the 2021 Inc. 5000 List.

To learn more about Stratasan’s company culture, core values, and job opportunities, visit Stratasan.com.

Media Contact: Jennifer Keller, Stratasan, jennifer@stratasan.com

About Stratasan, LLC

Nashville-based Stratasan was founded to change the way hospitals and health systems use data to achieve strategic growth. Stratasan is a leading provider of advanced data analytics and market intelligence to healthcare strategic planning and marketing professionals delivered via cloud services. A high-growth healthcare technology company, Stratasan works with more than 1,000 hospitals across 40+ states to remove the roadblock of endless data analysis and progress to the important work of growth planning. For more information, visit http://www.stratasan.com.

Share article on social media or email:

It is our company’s mission to improve the quality of life by helping our customers deliver safe and effective medical devices to patients and clinicians around the world.

INDIANAPOLIS (PRWEB)
November 17, 2021

Greenlight Guru, pioneer of the only dedicated Medical Device Success Platform (MDSP), today announced the launch of Guru Assist, a flexible way to leverage medical device expert assistance. This new service offering provides Greenlight Guru expert help exactly when and where customers need it with on-demand assistance accessed from where people are working—the Greenlight Guru platform.

Getting a medical device to market while navigating regulations is complicated, and time is valuable. Historically, medical device teams in need of help engaged outside consultants or spent time on research. Both of these options are either costly or time consuming. With Guru Assist, customers contact Greenlight Guru’s customer success team real-time from within the software and have an industry sounding board on best practices right when they need it, in addition to expedited software support.

“It is our company’s mission to improve the quality of life by helping our customers deliver safe and effective medical devices to patients and clinicians around the world,” said Francesca Cruz, Vice President of Customer Success at Greenlight Guru, “To do this, we believe we must democratize access to best practices and knowledge around the ever-changing medical device industry. Our team of Gurus, who are tenured medical device experts, have proven invaluable to our customers throughout their commercialization journey. Now, we’re excited to be the first to offer truly on-demand access to these Gurus. With Guru Assist, our customers have a lifeline to our expert team, and they can engage those Gurus directly in our application using live chat. This will help our customers get the answers they need, when they need them, from a trusted source they can rely on.”

This service offering will allow medical device professionals to receive context-rich answers to their most timely questions. Example Guru Assist queries include:

• 
  What standard operating procedure templates are most important for our company’s stage?
• Can you recommend a naming schema for the documents in my QMS?
• How should I run an effective design review using Greenlight Guru
• How often should we run internal audits?
• Can you give me a few examples of design inputs?

This launch follows the release of Intelligent Document Management powered by Halo℠ — a revolutionary technology that will transform the way you manage change by embedding new artificial intelligence (AI) and machine learning (ML) capabilities into your workflow to create efficiencies and improve quality across your change management process. To get your free demo of Guru Assist by Greenlight Guru, please visit https://www.greenlight.guru/services-overview

###

About Greenlight Guru

Greenlight Guru is the only quality management software platform designed specifically for medical device companies. The platform helps companies bring safer products to market faster, simplifies FDA and ISO regulatory compliance and provides a single source of truth by connecting the management of all quality processes like CAPAs, risk, audits and more. Greenlight Guru’s platform is used by thousands of users across the globe to push beyond baseline compliance and achieve True Quality for their medical devices. For more information, visit http://www.greenlight.guru.

Media Contact

Naomi Gollmer

naomi.gollmer@greenlight.guru

(419) 518-0067

Share article on social media or email:

“It is always a privilege to educate others and discuss the latest techniques using the Mako system. This exchange of knowledge between medical professionals at the conference makes us all better at what we do,” says Dr. Frederick F. Buechel

NEW YORK (PRWEB)
November 17, 2021

On Tuesday, August 31, 2021, the digital event, “Mako™ Smart Robotics:10 years of Experience Clinica San Francesco in Verona,” took place. This conference was sponsored by the Verona Medical Association and the Università Degli Studi of Verona. It was organized to commemorate the tenth anniversary of the first robotic orthopedic surgery operation with the Mako system performed in Italy by Dr. Piergiuseppe Perazzini, director of Orthopaedic and Traumatology Functional Unit and Chief of Orthopaedics at Clinica San Francesco – Verona, Italy. Dr. Perazzini previously trained with Dr. Buechel in 2011 on the Mako robotic-arm assisted joint replacement system.

During the conference, Dr. Frederick Buechel shared his expansive knowledge and cutting-edge work as an expert Mako robotic surgeon, instructor and surgeon proctor. Dr. Buechel has performed over 1500 Mako™ robotic knee and hip procedures in the USA, Asia, Australia and Europe, and he has taught hundreds of surgeons around the world how to use the Mako™ robotic-arm assisted joint replacement system. The online event was attended by major Italian, European and American experts in robotic orthopedic surgery and the organizations that have an important role in the field. The speakers shared their experience, advanced innovations, benefits and future prospects. The high-technology robotic platform for Mako robotic surgery was developed in the USA by the firm Stryker and introduced to Italy in 2011 by AB Medica. Currently, there are more than 1000 Mako robotic systems installed worldwide, of which 30 are in Italy (one of the first European countries for a number of robotic platforms installed).

“It is always a privilege to educate others and discuss the latest techniques using the Mako system. This exchange of knowledge between medical professionals at the conference makes us all better at what we do,” says Dr. Frederick F. Buechel

More about Frederick F. Buechel, Jr. MD:

Frederick F. Buechel, Jr. MD, is a board-certified orthopedic surgeon and the founder of the Robotic Joint Center, located in New York City and Taipei Postal Hospital in Taiwan. Dr. Buechel’s experience, skill and deep understanding of the robotic system’s capabilities make him a sought-after surgeon. Dr. Buechel has helped surgically launch Mako™ robotic joint replacement programs in the USA, Australia, China, Hong Kong, Taiwan, Thailand, Singapore, Vietnam, Greece, Turkey and Italy. Dr. Beuchel’s NYC practice is located at 737 Park Avenue 1C in New York, NY. For more information or to schedule a consultation please call 212-308-3089 or visit http://www.roboticjointcenter.com.

Share article on social media or email:

“We are honored to be partnering with SHARE Village to distribute these meals to veterans and those in need to show them they haven’t been forgotten, especially for Thanksgiving.

LAS VEGAS (PRWEB)
November 17, 2021

Planet 13, a leading vertically-integrated national cannabis company is famous for doing everything bigger and that also applies to giving back. On November 22nd, Planet 13 & Trece (P13’s on-site restaurant) will be sponsoring 200 Thanksgiving meals and donating them to local non-profit, SHARE Village Las Vegas.

“From the beginning we have made it our mission to give back to the community we love,” said David Farris, Planet 13 V.P. of Sales and Marketing. “We are honored to be partnering with SHARE Village to distribute these meals to veterans and those in need to show them they haven’t been forgotten, especially for Thanksgiving.”

The meals will be made at Plant 13’s Trece restaurant and delivered to SHARE Village located at 50 N. 21st Street, Las Vegas. Planet 13 will be dropping off the meals at noon in its Planet 13 shuttle bus.

“There’s nothing more rewarding for our team than making delicious meals for a special group of people who might not have the means to afford a Thanksgiving dinner,” said Manny Sanchez, Trece Executive Head Chef. “We will be putting a little extra TLC into prepping these 200 meals for these deserving recipients.”

SHARE Village Las Vegas provides direct relief to individuals, families and veterans in need of emergency food assistance, job referrals, affordable housing, medical and mental health services and more.

“We are so grateful for this timely and generous donation from Planet 13,” said Dr. Arnold Stalk, CEO of SHARE Village. “Everyone deserves dignity, and these meals show those we serve that they matter.”

For additional information regarding SHARE Village Las Vegas visit sharelasvegas.org

About Planet 13

Planet 13 (http://www.planet13holdings.com) is a vertically integrated cannabis company, with award-winning cultivation, production and dispensary operations in Las Vegas and dispensary operations in Orange County. Planet 13’s mission is to build a recognizable global brand known for world-class dispensary operations and a creator of innovative cannabis products. Planet 13’s shares trade on the Canadian Stock Exchange (CSE) under the symbol PLTH and OTCQX under the symbol PLNHF.

About Trece Eatery + Spirits

Trece Eatery + Spirits is a greenhouse-inspired culinary experience featuring a local and tourist-friendly atmosphere with signature Mexican dishes, artisan pizzas and handcrafted specialty cocktails. The 5,500-sq. ft. space offers a full bar including 12 beers on tap, kitchen and lounge available for private events. Trece is located inside the Planet 13 SuperStore Entertainment Complex at 2548 W. Desert Inn Rd, just steps from the iconic Las Vegas Strip and is open from 9 a.m. to 9 p.m. Sunday through Thursday, and 9 a.m. to 10 p.m. on Friday and Saturday. Pick-up and delivery options are available through Grubhub. For more information or to browse the menus visit TreceLasVegas.com.

Cautionary Note Regarding Forward-Looking Information

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to the ongoing operations of the Planet 13 Holdings, Inc. (the “Company”) and future charitable initiatives.

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: risks associated with COVID-19 and other infectious diseases presenting as major health issues; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the Nevada cannabis market and changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insurance to cover risks and hazards; and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution and sale of cannabis and cannabis related products in the State of Nevada; and employee relations. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

The Company is indirectly involved in the manufacture, possession, use, sale and distribution of cannabis in the recreational and medicinal cannabis marketplace in the United States through licensed subsidiary entities in states that have legalized marijuana operations, however, these activities are currently illegal under United States federal law. Additional information regarding this and other risks and uncertainties relating to the Company’s business, including COVID-19, are contained under the heading “Risk Factors” and elsewhere in the Company’s annual information form dated April 5, 2021, filed on its issuer profile on SEDAR at http://www.sedar.com.

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

For further inquiries, please contact:

Robert Groesbeck or Larry Scheffler Co-Chief Executive Officers

ir@planet13lasvegas.com

Share article on social media or email:

The aim of this presentation is to identify bioassays commonly applied to water extracts and provide guidance on assay selection and subsequent interpretation.

TORONTO (PRWEB)
November 17, 2021

Human-impacted surface, ground and drinking water can contain a complex mixture of micropollutants, such as pharmaceuticals, pesticides and industrial compounds. These potentially harmful chemicals are often found at low concentrations, and targeted chemical analysis cannot detect all the hazards present in a sample. Suspect screening and non-target analysis can identify a larger number of compounds but cannot provide information about the potential toxic effects of the micropollutant mixture.

Bioassays can account for mixture effects that targeted chemical analysis can miss and are risk-scaled as more potent chemicals have a greater effect in the assay. Consequently, effect-based methods have been recommended to complement chemical analysis in water quality monitoring. Bioassays based on different stages of cellular toxicity pathways including induction of xenobiotic metabolism, receptor-mediated effects, adaptive stress responses and apical effects have been widely applied to evaluate the effect of different water extracts.

The aim of this presentation is to identify bioassays commonly applied to water extracts and provide guidance on assay selection and subsequent interpretation. Examples will be given for how cell-based assays have been utilized to analyze important chemicals of concern, as well as complex mixtures. Data analysis including bioanalytical equivalent concentrations (BEQ), limit of detection (LOD) and effect concentration (EC) will be described.

Register for this webinar to discover how cell-based assays can help improve water quality assessments with an emphasis on potential health effects of complex mixtures of micropollutants.

Join Jack Vanden Heuvel, Professor of Molecular Toxicology, Penn State University and CSO, INDIGO Biosciences for the live webinar on Thursday, December 9, 2021 at 1pm EST.

For more information, or to register for this event, visit Biomonitoring: Relevance of Bioassays in Water Treatment.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

Register for this webinar to learn about how agile and scalable FSP models can remove the burdens of employment, day-to-day management requirements and operational delivery.

TORONTO (PRWEB)
November 17, 2021

In the ever-changing biopharmaceutical and biotechnology clinical development landscape, the functional service provider (FSP) model has evolved, enabling companies of all sizes and capabilities to be successful. The art of FSP is that it provides flexible, scalable, fit-for-purpose models.

Some organizations may focus on the science, so they choose a traditional FSP model of managing specific functional activities, thus increasing productivity and streamlining processes, which enables them to balance their execution and expertise and keep their projects on the right path. Other companies may need to scale rapidly and accelerate development of another portfolio of projects. They may choose an integrated single-source solution with a global network of multi-functional comprehensive capabilities that can simplify, accelerate and de-risk their unique needs.

An FSP service offering allows separation of core/non-core capabilities within an organization and allows for a choice of functional partners who specialize in services, such as clinical, regulatory, biometrics (DM, BIOS and MW) and drug safety for a scalable team to operationalize functional service(s) alongside an in-house team as a collaborative partner.

Register for this webinar to learn about how agile and scalable FSP models can remove the burdens of employment, day-to-day management requirements and operational delivery.

Join expert speakers from TFS HealthScience, Kymberli Shropshire, Global Head of Functional Service Partnerships; Ian Kovacs, Exec. Director of Safety and Pharmacovigilance; Alison Sampson, Head of Pediatrics, Rare Diseases, Orphan Products Europe; and Dorothy Blythe, Principal Clinical Data Manager, for the live webinar on Thursday, December 9, 2021 at 2pm EST.

For more information, or to register for this event, visit Modernized Approach to Functional Service (FSP): A Necessary Evolution on the Road to True Partnership.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

FAScinate Therapeutics

We are excited about the prospect of KM-819 for Parkinson’s disease with Phase 2 trials looking for evidence of disease modifying effects. KM-819 shows a promising neuroprotection efficacy in dopaminergic cells including GBA mutation, as well as clearing the alpha-synuclein.

SAN DIEGO (PRWEB)
November 17, 2021

Clinical stage drug development company FAScinate Therapeutics, Inc. today announced that its Investigational New Drug (IND) application for Phase 2 trials of its Parkinson’s Disease treatment “KM-819” has been cleared by the United States Food and Drug Administration (FDA). The trial design, as approved by the FDA, is intended to evaluate the disease-modifying efficacy of KM-819 in slowing or stopping the progression of Parkinson’s disease. The goal is to evaluate the pharmacokinetics and safety and preliminary efficacy in early to mid-stage patients, including GBA mutation carriers, with two-year treatments.

The approved trial design has a dose escalation stage where the pharmacokinetics and safety will be assessed at several different doses beyond the dose tested in Phase 1 trials, and will be followed by a 24-month trial of the selected doses with both safety and efficacy endpoints of KM-819 on the progression of Parkinson’s Disease.

Parkinson’s Disease is a neurodegenerative disease, and the second most common central nervous system (CNS) disease following Alzheimer’s Disease. It disrupts normal movement behaviors and also causes several non-movement symptoms. It is known to be caused by the premature death of dopaminergic neuron cells in the midbrain. Currently, there are many symptomatic treatment drugs for the disease but effective disease-modifying therapies for stopping or slowing down the progression are completely absent despite significant need.

KM-819 is a potent inhibitor of FAF1, a key regulatory protein in cell death pathways, apoptosis, and necrosis, and leads to neuronal cell protection in pre-clinical studies. A higher level of FAF1 is found in Parkinson’s Disease patients and could contribute to the early cell death. Thus, FAF1 may be a significant target when it comes to the development of disease modifying treatments for Parkinson’s Disease

patients.

FAScinate Therapeutics said, “We are excited about the prospect of KM-819 for Parkinson’s disease with Phase 2 trials looking for evidence of disease modifying effects. KM-819 shows a promising neuroprotection efficacy in dopaminergic cells including GBA mutation, as well as clearing the alpha-synuclein.”

About KM-819

KM-819 is a small molecule developed as an inhibitor for FAF1, a proapoptotic protein, targeting various degenerative diseases. It has shown a superior neuroprotective efficacy in Parkinson’s Disease models, and entered into clinical trials with the aim of proving efficacy in human patients. KM-819 may be also explored in other indications for different degenerative diseases including multiple system atrophy (MSA). It shows an excellent safety profile in both long-term animal toxicology studies and the humanclinical trial Phase 1 study that has been completed.

About Parkinson’s Disease

Parkinson’s Disease is the second most common chronic CNS disease, next to Alzheimer’s Disease, estimated to afflict 6 to 10 million patients worldwide and 1 million in the United States. It is more common in elderly people, with 2-3 % aged 65 and over now affected, and there are expectations of an increase in the number of patients as the population continues to age. The current standard of care is symptomatic treatments by supplementing dopamine or dopamine agonists or analogous mechanisms, so a disease modifying treatment is one of the major unmedical needs in order to address the impact of Parkinson’s Disease.

About FAScinate Therapeutics Inc.

FAScinate Therapeutics Inc., a subsidiary of the Korean Biotech company Kainos Medicine Inc., is a clinical stage biotechnology company based in San Diego, California focused on the development of novel therapeutics for central nervous system diseases. FAScinate has licensed KM-819 for clinical development and commercialization from Kainos Medicine, and is moving it to phase 2 study in the US for Parkinson’s Disease. For more information, please visit http://www.fascinatetherapeutics.com

Forward-Looking Statements

This press release contains forward-looking statements. These statements relate to, among other things, the potential of KM-819 as a disease-modifying therapeutic stopping or slowing the progression of Parkinson’s disease. These statements are identified by their use of terms and phrases such as “will,” “potentially,” “suggest,” “targeting,” “expect,” “aiming,” “prove,” “estimated,” and other similar terms and phrases. These statements are based on estimates, assumptions, and projections that may not be proven to be accurate, and actual results could differ materially from those anticipated due to known and unknown risks, uncertainties, and other factors. FAScinate Therapeutics undertakes no obligations to update publicly any forward-looking statements contained in this press release as a result of new information, future events or changes in FAScinate Therapeutics’s expectations.

Share article on social media or email: